Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 03, 2023
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy Study of SOM230 s.c. in Cluster Headache
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 02, 2015
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 20, 2012
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 11, 2012
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 17, 2012
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 05, 2011
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable